Desmoplastic Small Round Cell Tumors in a Young Man

Genryu Hirano¹, Makoto Irie¹, Yuta Nakashima², Satoshi Shakado¹, Tetsuro Sohda¹, Toshihiro Tanaka², Yasushi Takamatsu², Mikiko Aoki³, Kazuo Tamura², Kazuki Nabeshima³ and Shotaro Sakisaka¹

Abstract

A previously healthy 18-year-old man was admitted to our hospital with abdominal pain in September 2010. We performed a percutaneous biopsy of multiple intrahepatic masses. A diagnosis of desmoplastic small round cell tumors was confirmed based on the presence of a polyphenotypic immunoprofile (positivity for EMA, vimentin, cytokeratin, desmin and WT1) and characteristic EWS-WT1 gene fusion. Because the mass had invaded the mesentery and the disease had disseminated to liver, the patient received palliative chemotherapy with carboplatin, paclitaxel, vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide and irinotecan. The maximal response to the chemotherapy was a partial remission. The patient died 20 months after diagnosis.

Key words: chemotherapy, desmoplastic small round cell tumor, EWS-WT1 gene fusion transcript, reverse transcriptase polymerase chain reaction


Introduction

Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive mesenchymal tumor that was first described as a separate identity in 1989 (1). Characterized by a predilection for young men, it typically presents as an intra-abdominal mass with multiple intra-peritoneal implants (2, 3). However, the site of origin may not be readily apparent (4). The diagnosis of DSRCT is established based on histology, immunochemistry and cytogenetics. Histological examinations reveal sheets or nests of uniform small, round or ovoid cells within a desmoplastic stroma (5, 6). DSRCT has a polyphenotypic immunoprofile and is positive for the EWS-WT1 fusion transcript (7, 8). Most patients are diagnosed in the advanced stage and have a poor prognosis. Despite the administration of intensive therapy, including surgery, radiotherapy and chemotherapy, the 5-year survival rate continues to be less than 15% (9-12). We herein report the case of a young man who was diagnosed with DSRCT and treated with combination chemotherapy.

Case Report

A previously healthy 18-year-old man was admitted to our hospital with upper abdominal pain in September 2010. He had a palpable mass measuring approximately 4.0 cm in diameter in the middle of the lower abdominal region. His liver was palpable 7 cm below the right costal margin. The results of liver function tests showed elevated levels of transaminases, alkaline phosphatase (ALP) and gammaglutamyl transpeptidase (GGT). The serum neuron specific enolase level was 46.0 ng/mL (normal range, 0-10) (Table). Ultrasonography showed multiple hypoechoic masses in the liver and a mass including spotty areas of calcification measuring 4.0 cm in diameter in the middle of the lower ab-
Abdominal computed tomography (CT) demonstrated the presence of a lower abdominal mass measuring 4.0 cm, hepatomegaly and multiple intrahepatic metastases. The lower abdominal mass exhibited less enhanced areas with spotty calcification (Fig. 2). Hybrid [18F] fluorodeoxyglucose-positron emission tomography ([18F]FDG-PET/CT) revealed multiple intrahepatic masses exhibiting accumulation of FDG (standardized uptake value (SUV) = 14.6, max) and a lower abdominal mass exhibiting accumulation of FDG (SUV = 6.60) (Fig. 3). Upper gastrointestinal endoscopy, double-balloon endoscopy and colonoscopy demonstrated no localized lesions. The histopathologic results of the biopsy of the intrahepatic masses showed proliferation of atypical cells with hyperchromatic nuclei forming irregularly shaped small nests accompanied by fibromyxoid stroma (Fig. 4). The tumor cells coexpressed an epithelial membrane antigen (EMA) (Dako, Glostrup, Denmark), a mesenchymal marker (vimentin) (Dako) and a neuronal marker (neuron specific enolase) (Dako). Other immunohistochemistry findings showed that the tumor cells were positive for cytokeratins (CAM5.2, AE1/AE3) (Becton Dickinson, San Jose, CA, USA) and WT1 (Santa Cruz Biotechnology, Heidelberg, Germany) and negative for c-kit (IBL, Fujioka, Japan), CD19 (Dako), CD30 (Dako) and CD34 (Immunotech, Marseille, France). Because the extraction of the messenger RNA was poor, the results of reverse transcriptase polymerase chain reaction (RT-PCR) for the EWS-WT1 gene fusion transcript were not confirmed. The characteristic reciprocal translocation that is specific to DSRCT was identified on fluorescence in situ hybridization (FISH) (Fig. 5A). Although the finding of positive cytokeratins were compatible with a diagnosis of epithelial tumors, a diagnosis of desmoplastic small round cell tumors was made due to the typical histological findings and karyotypic alterations. The patient was treated with chemotherapy consisting of carboplatin (AUC 6) plus paclitaxel (200 mg/m²) (CBDCA/PTX). Six courses of chemotherapy were administered, and the tumor size was significantly. He achieved partial remission according to the RECIST criteria (13) (Response Evaluation Criteria in Solid Tumors). His general condition recovered and was sustained for two months. However, after six months, the patient again developed an increased level of neuron-specific enolase (NSE) and enlarged tumor size. He underwent a second liver biopsy to evaluate the histological changes, leading to successful detection of the EWS-WT1 fusion transcript on RT-PCR, which revealed a fusion product in EWS with exon 8 of WT1 and exon 9 of WT1 (Fig. 5B). The above molecular studies confirmed the diagnosis of desmoplastic small round cell tumors. The patient was then treated with a second-line chemotherapy P6 protocol consisting of seven courses of chemotherapy with cyclophosphamide (2,100 mg/m²), doxorubicin (25 mg/m²) and vincristine (0.67 mg/m²) (HD-CA V) alternating with ifosfamide (3,000 mg/m²) and etoposide (250 mg/m²). He responded to this regimen only transiently, and soon after the seven courses of second-line therapy, progressive disease was noted. We administered salvage chemotherapy with irinotecan (CPT-11 at 250 mg/m²). The lower abdominal tumor appeared to be stabilized. However, the liver tumors progressed. We decided not to continue with further treatment due to the rapid deterioration of the patient’s condition. He died 20 months after receiving the initial diagnosis (Fig. 6). An autopsy was not performed.

**Table. Laboratory Data on Admission**

<table>
<thead>
<tr>
<th>Hematology</th>
<th>Biochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC 6,300 / μL</td>
<td>TP 8.0 g/dL</td>
</tr>
<tr>
<td>RBC 547×10⁶ / μL</td>
<td>Alb 5.0 g/dL</td>
</tr>
<tr>
<td>Hb 17.1 g/dL</td>
<td>T-Bil 0.8 mg/dL</td>
</tr>
<tr>
<td>Ht 49.5%</td>
<td>AST 193 IU/L</td>
</tr>
<tr>
<td>Pt 19.2×10⁹ / μL</td>
<td>ALT 162 IU/L</td>
</tr>
<tr>
<td>Tumor marker</td>
<td>LDH 687 IU/L</td>
</tr>
<tr>
<td>NSE 46.0 mg/mL</td>
<td>ALP 421 IU/L</td>
</tr>
<tr>
<td>(normal range &lt;10 mg/mL)</td>
<td>γ-GTP 195 IU/L</td>
</tr>
<tr>
<td>CA125 31 U/mL</td>
<td>BUN 9 mg/dL</td>
</tr>
<tr>
<td>(normal range &lt;35 IU/ml)</td>
<td>Cr 0.7 mg/dL</td>
</tr>
<tr>
<td>Soluble IL-2R 623 IU/mL</td>
<td>Na 141 mEq/L</td>
</tr>
<tr>
<td>(normal range &lt;196 IU/mL)</td>
<td>K 4.5 mEq/L</td>
</tr>
<tr>
<td>Cl 103 mEq/L</td>
<td>CRP 0.61 mg/dL</td>
</tr>
</tbody>
</table>
Discussion

DSRCT is an extremely rare malignancy that was first described by Gerald and Rosai in 1989 (1). DSRCT is predominantly observed in adolescents and young adults. The mean age at diagnosis is approximately 22 years, and the male to female ratio is 4:1 (2, 3). DSRCT most frequently arises in the peritoneal cavity and may present with peritoneal “caking” of tumor implants (9). Because the tumors can have various differentiations such as epithelial, mesenchymal or neuronal differentiation with coexpression of cytokeratin, EMA, desmin, vimentin and/or NSE, it is difficult to diagnose DSRCT solely based on the immunohistochemical findings (11, 12). However, the cytogenetic and molecular genetic analyses of small round cell tumors reveal distinctive findings that help in reaching a diagnosis. The chromosomal translocation t (11;22)(p13;q12), which leads to fusion of the WT1 and EWS genes, is specific to DSRCT, and the presence of this fusion gene assists with making the final diagnosis (7, 8). Making the differential diagnosis is crucial, since treatment strategies differ. The molecular diagnosis of

Figure 2. (A)-(C) Triple phase helical dynamic CT of the liver revealed the presence of hepatomegaly and multiple intrahepatic tumors. (A) Arterial phase CT showed heterogeneous masses in the liver. (B)(C) Portal venous phase and delayed phase CT showed heterogeneous hypodense pickup masses in the liver. (D) A lower abdominal mass measuring 4.0 cm exhibited less enhanced areas of spotty calcification (arrow).

Figure 3. (A) 18FDG-PET/CT imaging showed multiple intrahepatic masses exhibiting accumulation of FDG (SUV= 14.6, max). (B) A lower abdominal mass demonstrated accumulation of FDG (SUV= 6.60).
Figure 4. (A) Light micrograph showing compact nests and sheets of small, round cells in fibro-myoid stroma on Hematoxylin and Eosin staining. Magnification 200×. (B) The section exhibited proliferation of atypical cells with hyperchromatic nuclei forming irregularly shaped small nests. (C) AE1/AE3 immunohistochemistry showed typical paranuclear dot-like staining. (D) The tumor cells exhibited a strong nuclear staining reaction for WT1.

Figure 5. (A) FISH demonstrated tumor cell nuclei with a combined normal red-green signal and a separate red and green signals, indicating the presence of translocation and amplification of the EWS gene (arrow). The red signals are centromeres and the green signals are telomeres. (B) Detection of the EWS-WT1 fusion transcript on RT-PCR revealed a fusion product in EWS with exon 8 of WT1 and exon 9 of WT1. Products ranging from 100 to 200 base pairs (bp) in lanes 1-3, confirming DSRCT, and the absence of amplification in the other lanes.
Ewing sarcoma/PNET (primitive neuroectodermal tumor) shows the chromosomal translocation t(11;22)(q24;q12). We can exclude the possibility of Ewing sarcoma/PNET, in this case based on the results of RT-PCR. Therefore, performing biopsies under laparotomy or conducting multiple core biopsies is recommended in order to obtain a sufficient quantity of tumor tissues which in turn can be utilized in relevant examinations. Since we did not obtain adequate tumor samples, we were unable to make a conclusive diagnosis of DSRCT after the initial liver biopsy. We were able to find the EWS-WT1 gene fusion transcript by examining the large sample obtained during the second liver biopsy.

A variety of treatment regimens to treat DSRCT are administered worldwide. Therefore, there is no standard treatment for this disease. Several treatment modalities, including chemotherapy, radiotherapy and debulking surgery, have been used to treat patients with DSRCT (8-12). However, reports regarding these treatments have focused on retrospective data obtained from small numbers of patients. Although DSRCT is known to be rather chemosensitive and radiosensitive, the response is rarely durable (12). There are only a few reports of the role of chemotherapy in such patients. Early treatments involve high-dose systemic polychemotherapy with alkylating agents and the P6 protocol employed at the Memorial Sloan-Kettering Cancer Center. The P6 protocol consists of seven courses of cyclophosphamide, doxorubicin, vincristine, ifosfamide, and etoposide (2, 9).

Our patient was treated with combination chemotherapy consisting of CBDCA/PTX as first-line chemotherapy, then subsequently treated with the P6 protocol as second-line chemotherapy followed by salvage chemotherapy treatment with irinotecan (CPT-11). Carboplatin and paclitaxel were chosen as the initial regimen of chemotherapy due to the initial diagnosis of carcinoma not otherwise specified (NOS) of unknown primary status, under the NCCN (National Comprehensive Cancer Network) guidelines. Considerable time had elapsed before the diagnosis of DSRCT was made. The maximum response in this case was a partial remission to the first-line chemotherapy, and the time to progression was six months. The patient was able to manage his ADLs alone with improvement in his abdominal pain associated with the presence of large abdominal masses, even during chemotherapy. Chemotherapy was beneficial for this patient with DSRCT and worth administering. Radiation therapy and volume-reduction surgery are frequently used in patients with advanced DSRCT. However, as the patient’s primary prognostic factor was regarded to be metastatic liver cancer and he was not troubled by his lower abdominal mass, we did not opt for these modalities. The prognosis of patients with DSRCT is generally poor. Despite the use of aggressive multimodal treatment, the median survival ranges from 17 to 25 months, with fewer than 20% of patients achieving 5-year survival (14).

In conclusion, we herein reported the case of a young man who was diagnosed with DSRCT and treated with combination chemotherapy. Molecular genetic studies using FISH and RT-PCR are quite helpful in diagnosing DSRCT. Therefore, the need to obtain a sufficient quantity of tumor tissue for molecular examinations should be emphasized. Our patient responded to polychemotherapy; however, the duration of the response was limited. Further studies are needed to establish a more comprehensive treatment strategy for this refractory disease.

The authors state that they have no Conflict of Interest (COI).

Appendix

This case study was presented at the 297th Kyushu branch meeting of the Japanese Society of Internal Medicine (May 2012, Fukuoka).
Acknowledgement

We would like to thank Dr. Y. Nakashima, Dr. T. Tanaka and Dr. Aoki for their support in diagnosing and treating the patient (Department of Medical Oncology, Hematology and Infectious Disease, Department of Pathology, Fukuoka University Faculty of Medicine).

References